Review on 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020 Emphasizing Intellectual Property and Regulatory Considerations for Reformulations and New Combinations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Review on 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020 Emphasizing Intellectual Property and Regulatory Considerations for Reformulations and New Combinations

Published:2023-08 Issue:8 Volume:112 Page:2146-2175
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Ravula Jyosna Devi,Nirogi Ramakrishna,Janodia Manthan D.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference59 articles.

1. Innovation in the pharmaceutical industry: new estimates of R&D costs;DiMasi;J Health Econ,2016

2. Diagnosing the decline in pharmaceutical R&D efficiency;Scannell;Nat Rev Drug Discov,2012

3. The value of drug repositioning in the current pharmaceutical market;Tobinick;Drug News Perspect,2009

4. Deconstructing the drug development process: the new face of innovation;Kaitin;Clin Pharmacol Ther,2010

5. Drug repurposing in pharmaceutical industry and its impact on market access: market access implications;Murteira;J Mark Access Health Policy,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP